<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02957266</url>
  </required_header>
  <id_info>
    <org_study_id>MOM-0001</org_study_id>
    <nct_id>NCT02957266</nct_id>
  </id_info>
  <brief_title>Cervical Cancer Radiotherapy by Use of VMAT, Individualized Polyradiosensitization and Interstitial Brachytherapy</brief_title>
  <acronym>CERVIPIB</acronym>
  <official_title>Improvement of Locally Advanced Cervical Cancer Radiotherapy Efficacy by Use of Volumetric Arc Therapy, Individualized Polyradiosensitization and Interstitial Brachytherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The National Center of Oncology, Azerbaijan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The National Center of Oncology, Azerbaijan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to define an effectiveness of concurrent chemoradiotherapy of
      cervical cancer patients treated by VMAT (volumetric arc therapy) based external beam
      radiotherapy, polyradiosensitization by cisplatin and gemcitabine and interstitial
      brachytherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Now cisplatin based concurrent chemoradiotherapy for cervical cancer is a standard treatment
      modality. But we consider that the treatment results could be improved by several ways: 1.
      use of VMAT (volumetric arc therapy) based external beam radiotherapy could decrease toxicity
      by reducing of unnecessarily irradiated tissue volumes; 2. in addition to cisplatin
      gemcitabine could enhance tumor cell damaging effect of radiation; 3. interstitial
      brachytherapy could provide higher radiation dose boost to high risk tumor volume while
      sparing surrounding organs at risk.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse Rate (local and/or distant) and Number of Deaths Due to Any Cause</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Progressive Disease</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute toxicity</measure>
    <time_frame>Up to 30 days after completion of radiation therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of late toxicity</measure>
    <time_frame>Up to 2 years after completion of radiation therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Classical treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Classical concurrent cisplatin based chemoradiotherapy of cervical cancer. PIK3CA, KRAS, BRAF and RRM1 mutations rates.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GemInterBraVMAT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent chemoradiotherapy of cervical cancer patients treated by VMAT (volumetric arc radiotherapy) based external beam radiotherapy, polyradiosensitization by cisplatin and gemcitabine and interstitial brachytherapy.
PIK3CA, KRAS, BRAF and RRM1 mutations rates.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Volumetric Arc Radiotherapy</intervention_name>
    <description>Volumetric Arc Radiotherapy</description>
    <arm_group_label>Classical treatment</arm_group_label>
    <arm_group_label>GemInterBraVMAT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Interstitial brachytherapy</intervention_name>
    <description>Interstitial High Dose Rate Brachytherapy</description>
    <arm_group_label>GemInterBraVMAT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Weekly Cisplatin</description>
    <arm_group_label>Classical treatment</arm_group_label>
    <arm_group_label>GemInterBraVMAT</arm_group_label>
    <other_name>CDDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Weekly Gemcitabine</description>
    <arm_group_label>GemInterBraVMAT</arm_group_label>
    <other_name>Gemcitabine Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>PIK3CA</intervention_name>
    <description>PIK3CA mutations rate</description>
    <arm_group_label>Classical treatment</arm_group_label>
    <arm_group_label>GemInterBraVMAT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>KRAS</intervention_name>
    <description>KRAS mutations rate</description>
    <arm_group_label>Classical treatment</arm_group_label>
    <arm_group_label>GemInterBraVMAT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>BRAF</intervention_name>
    <description>BRAF mutations rate</description>
    <arm_group_label>Classical treatment</arm_group_label>
    <arm_group_label>GemInterBraVMAT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RRM1</intervention_name>
    <description>RRM1 mutations rate</description>
    <arm_group_label>Classical treatment</arm_group_label>
    <arm_group_label>GemInterBraVMAT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Histologically confirmed primary invasive carcinoma of the uterine cervix Previously
        untreated disease Any cell type Stage IB2, IIA, IIB, IIIA, IIIB, or IVA Para-aortic lymph
        nodes negative by radiologic evaluation or by biopsy if CT scan is suspicious for
        adenopathy No known metastases to scalene nodes or other organs outside the radiotherapy
        field Study enrollment within 8 weeks of diagnosis Performance status - GOG 0-2 Absolute
        neutrophil count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Bilirubin no
        greater than 1.5 times normal SGOT no greater than 3 times normal Creatinine less than 2.0
        mg/dL No renal abnormalities (e.g., pelvic kidney, horseshoe kidney, or renal
        transplantation) that would require modification of radiotherapy fields No bilateral
        ureteral obstruction allowed unless treated with stent or nephrostomy tube Not pregnant
        Fertile patients must use effective contraception No septicemia or severe infection No
        circumstance that would preclude study completion or follow-up No other malignancy within
        the past 5 years except nonmelanoma skin cancer No prior cytotoxic chemotherapy No prior
        pelvic or abdominal radiotherapy No prior therapy for this malignancy

        Exclusion Criteria:

        Pregnancy or Breast-Feeding: Pregnant or breast-feeding women will not be entered on this
        study due to risks of fetal and teratogenic adverse events.(Note: Serum Pregnancy tests
        must be obtained in women of child bearing potential). Sexually active females may not
        participate unless they have agreed to use an effective contraceptive method (such as
        abstinence, diaphragm, condom, or intrauterine device) to prevent pregnancy for the
        duration of the study.

        Growth factor(s): Growth factors that support platelet or white cell number or function
        must not have been administered within the past 28 days.

        Erythropoietic drug(s): Erythropoietin or related hormones must not have been administered
        within the past 28 days.

        Infection: Patients who have an uncontrolled infection. Evidence of distant metastases
        Prior invasive malignancy (except non-melanomatous skin cancer), unless disease free for a
        minimum of 3 years.

        Prior systemic chemotherapy within the last three years. Prior radiotherapy to the pelvis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kamal Akbarov, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Center of Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kamal Akbarov, PhD</last_name>
    <phone>+994503362974</phone>
    <email>akperovkamal@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Center of Oncology</name>
      <address>
        <city>Baku</city>
        <zip>AZ1011</zip>
        <country>Azerbaijan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aziz Aliyev, Professor</last_name>
      <phone>+994504807021</phone>
      <email>internationalnoc@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Azerbaijan</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2016</study_first_submitted>
  <study_first_submitted_qc>November 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2016</study_first_posted>
  <last_update_submitted>November 14, 2016</last_update_submitted>
  <last_update_submitted_qc>November 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The National Center of Oncology, Azerbaijan</investigator_affiliation>
    <investigator_full_name>Kamal Akbarov</investigator_full_name>
    <investigator_title>Radiation Oncologist, PhD</investigator_title>
  </responsible_party>
  <keyword>cervical cancer</keyword>
  <keyword>interstitial brachytherapy</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>volumetric arc therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

